Phathom Gross Profit from 2010 to 2025

PHAT Stock

USD 6.79 0.17 2.44%

Phathom Pharmaceuticals Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Phathom Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

592.2 K

Current Value

621.9 K

Quarterly Volatility

341.2 K

Credit Downgrade

Yuan Drop

Covid

Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 9.5 M, Depreciation And Amortization of 694.3 K or Interest Expense of 50.7 M, as well as many indicators such as Price To Sales Ratio of 549, Dividend Yield of 0.0 or Days Sales Outstanding of 701. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Latest Phathom Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Phathom Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Phathom Pharmaceuticals minus its cost of goods sold. It is profit before Phathom Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Phathom Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 21.95 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

Phathom Gross Profit Regression Statistics

	Arithmetic Mean	13,007
	Coefficient Of Variation	2,623
	Mean Deviation	211,261
	Median	(8,000)
	Standard Deviation	341,221
	Sample Variance	116.4B
	Range	1.2M
	R-Value	0.26
	Mean Square Error	116.6B
	R-Squared	0.07
	Significance	0.34
	Slope	18,302
	Total Sum of Squares	1.7T

Phathom Gross Profit History

	2025	621.9 K
	2024	592.2 K
	2023	515 K
	2022	-620 K
	2021	-521 K
	2020	-300 K

Other Fundumenentals of Phathom Pharmaceuticals

Gross Profit Margin

Phathom Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Long Term Debt	Long Term Debt Total	Common Stock	Property Plant Equipment	Net Receivables
Total Assets		0.07	0.06	0.86	-0.94	-0.89	0.87	0.92	0.82	0.61	0.92	1.0	1.0	-0.04	0.85	0.78	0.9	0.78	0.72
Total Stockholder Equity	0.07		1.0	-0.1	-0.26	0.24	-0.03	0.13	-0.43	0.78	0.22	0.08	0.09	0.45	-0.41	-0.33	-0.34	-0.25	-0.45
Net Tangible Assets	0.06	1.0		-0.1	-0.25	0.25	-0.03	0.13	-0.44	0.77	0.21	0.07	0.08	0.45	-0.42	-0.34	-0.35	-0.26	-0.46
Current Deferred Revenue	0.86	-0.1	-0.1		-0.8	-0.95	0.91	0.93	0.84	0.52	0.88	0.86	0.84	0.04	0.85	0.88	0.82	0.73	0.65
Net Debt	-0.94	-0.26	-0.25	-0.8		0.81	-0.8	-0.86	-0.75	-0.76	-0.85	-0.94	-0.94	-0.06	-0.65	-0.58	-0.73	-0.67	-0.68
Retained Earnings	-0.89	0.24	0.25	-0.95	0.81		-0.85	-0.91	-0.92	-0.41	-0.87	-0.89	-0.88	0.2	-0.93	-0.91	-0.89	-0.77	-0.76
Accounts Payable	0.87	-0.03	-0.03	0.91	-0.8	-0.85		0.86	0.75	0.49	0.83	0.87	0.84	0.32	0.78	0.77	0.83	0.9	0.59
Capital Surpluse	0.92	0.13	0.13	0.93	-0.86	-0.91	0.86		0.73	0.69	0.99	0.93	0.92	-0.02	0.81	0.85	0.77	0.7	0.52
Total Liab	0.82	-0.43	-0.44	0.84	-0.75	-0.92	0.75	0.73		0.2	0.66	0.81	0.81	-0.28	0.89	0.78	0.91	0.75	0.94
Net Invested Capital	0.61	0.78	0.77	0.52	-0.76	-0.41	0.49	0.69	0.2		0.73	0.63	0.63	0.28	0.19	0.24	0.23	0.2	0.1
Short Long Term Debt	0.92	0.22	0.21	0.88	-0.85	-0.87	0.83	0.99	0.66	0.73		0.92	0.92	-0.01	0.77	0.81	0.74	0.67	0.46
Total Current Assets	1.0	0.08	0.07	0.86	-0.94	-0.89	0.87	0.93	0.81	0.63	0.92		1.0	-0.04	0.84	0.78	0.89	0.77	0.72
Net Working Capital	1.0	0.09	0.08	0.84	-0.94	-0.88	0.84	0.92	0.81	0.63	0.92	1.0		-0.09	0.84	0.77	0.88	0.75	0.72
Short Term Debt	-0.04	0.45	0.45	0.04	-0.06	0.2	0.32	-0.02	-0.28	0.28	-0.01	-0.04	-0.09		-0.3	-0.25	-0.16	0.18	-0.33
Long Term Debt	0.85	-0.41	-0.42	0.85	-0.65	-0.93	0.78	0.81	0.89	0.19	0.77	0.84	0.84	-0.3		0.96	0.96	0.74	0.77
Long Term Debt Total	0.78	-0.33	-0.34	0.88	-0.58	-0.91	0.77	0.85	0.78	0.24	0.81	0.78	0.77	-0.25	0.96		0.87	0.67	0.59
Common Stock	0.9	-0.34	-0.35	0.82	-0.73	-0.89	0.83	0.77	0.91	0.23	0.74	0.89	0.88	-0.16	0.96	0.87		0.81	0.84
Property Plant Equipment	0.78	-0.25	-0.26	0.73	-0.67	-0.77	0.9	0.7	0.75	0.2	0.67	0.77	0.75	0.18	0.74	0.67	0.81		0.63
Net Receivables	0.72	-0.45	-0.46	0.65	-0.68	-0.76	0.59	0.52	0.94	0.1	0.46	0.72	0.72	-0.33	0.77	0.59	0.84	0.63

Click cells to compare fundamentals

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	592.2 K	621.9 K
Gross Profit Margin	0.68	0.61

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC